Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Liver Fibrosis and Five Year Survival of Hepatocellular Cancer Cases Undergoing Transcatheter Arterial Chemo Embolization Using Small Doses

  • Li, Hong (Department of Radiology, Renhe Hospital) ;
  • Hu, Yaohong (Three Gorges University) ;
  • Li, Na (Three Gorges University) ;
  • Zhou, Yan (Department of Radiology, Renhe Hospital)
  • Published : 2012.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To investigate liver fibrosis, TGF-${\beta}1$ levels and curative effects on hepatocellular carcinoma (HCC) with small and conventional dose perfusion chemotherapy by transcatheter arterial chemo embolization (TACE). Methods: Thirty-six hepatocellular carcinoma patients not indicated for surgical resection underwent super-selective transcatheter arterial chemoembolization, divided into small dose (n=15) and conventional dose (n=21) chemotherapy groups. Results: With conventional doses, four indices of liver fibrosis focusing on hyaluronate acide (HA), human procollagen type-III (hPC-III), collagen type-Ⅳ (Ⅳ-C) and transforming growth factor-${\beta}l$ (TGF-${\beta}1$) were obviously increased postoperative compared with preoperative (P<0.01); in contrast, with small doses there were no significant differences except for TGF-${\beta}1$. Five year survival demonstrated no significant differences between the two groups (P>0.05). Conclusion: To hepatocellular carcinoma patients treated by TACE, reducing doses of chemotherapy drugs can reduce progress of liver fibrosis, without impacting on five year survival.

Keywords

References

  1. Bruix J (1997). Treatment of hepatocellular carcinoma. Hepatology, 25, 259-62. https://doi.org/10.1002/hep.510250201
  2. Camma C, Schepis F, Orlando A, et al (2008). Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology, 224, 47-54.
  3. chen MS, Li JQ, Zhang YQ, et al (2002). High does iozedized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol, 8, 74.
  4. Chen Y, Feng Y, Dai L, et al (2003). Screening and evaluation of non-traumatic diagnostic indexes to compensatory hepatic cirrhosis. Chinese Hapar Disease J, 11, 220-5.
  5. Chung JW, Park JH, Han JK, et al (2007). Hepatic tumors: predisposing fators for complications of transeatheter oily chemoembolization. Radiology, 198, 33-40.
  6. Chung JW, Park JH, Han JK, et al (1996). Hepatic tumors: predispo sing factors for complications of transcatheter oily chemoembolization. Radiology, 198, 33-40. https://doi.org/10.1148/radiology.198.1.8539401
  7. Feng G, Wu H, Xu L, et al (2002). The related to the fibrotic indicators of primary hepatocellular carcinoma patients after transcatheter arterial chemoembolization. Chinese J of Hepatobiliary Surg, 8, 414-6.
  8. Hu D, Li Z, Wang N, et al (2002). TACE treatment of Hepatic Carcinoma: A Comparative study of low dose versus conventional dose. Clin Radiol J, 23, 502-6.
  9. Ikeda K, Kumada H, Saitoh S, et al (2001). Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma: an analysis by the cox proportional hazard model. Cancer, 68, 2150-4.
  10. Kamada K, Nakanishi T, Kitamoto M, et al (2001). Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol, 12, 847-54. https://doi.org/10.1016/S1051-0443(07)61510-3
  11. Kamada K, Nakanishi T, Kitamato M, et al (2009). Long-term prognosis of patients undergoing transcatheter arterial chenmoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin liopiodol suspension and doxorubicin hydrocholoride emulsion. J Vasc Interv Radiol, 12, 843-7.
  12. Li H, Hu D, Zhao Y, et al (2000). The relationship between curative effect of hepatic arterial chemoembolization and dose of Iodized Oil. China Hepatol J, 12, 235-6.
  13. Lu W, Li Y, He X, et al (2004). A comparative study on the changes of serum fibrosis indicators after TACE with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma. J Interv Radiol, 13, 247-9.
  14. Lu W, Lu S (2006). Progress in diagnosis and treatment of liver fibrosis. Int J Digest Dis, 26, 13-6.
  15. Lu W, Li Y (2002). Hepatic carcinoma treated with trancatheter arterial chemoembolization. Clin Radiol J, 21, 735.
  16. Lu W, Li Y, Li Z, et al (2003). A comparative study on necrosis and apoptosis of hepatocellular carcinoma cells after TACE with use of low-dose and conventional-dose anticancer drugs. Chinese J Radiol, 37, 232-7.
  17. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guide lines to evaluate the response to treatment in solidtumors. JNCI, 92, 205-16. https://doi.org/10.1093/jnci/92.3.205
  18. Xiao C, Zheng L, Jiang X, et al (1997). Observation of liver damage caused by hepatic arterial chemoembolization. China Radiol J, 31, 777-9.
  19. Yan L (2002). Liver Surgery. Peking: The People's Medical Publishing House, 263-509.
  20. Zhu S, Shan H, Huang M, et al (2000). The content changes of serum liver fibrosis indicators after transarterial chemoembolization for primary hepatic carcinoma and their clinical significance. J Clin Radiol, 19, 208-9.

Cited by

  1. Impact of Low Versus Conventional Doses of Chemotherapy During Transcatheter Arterial Chemo-embolization on Serum Fibrosis Indicators and Survival of Liver Cancer Patients vol.13, pp.9, 2012, https://doi.org/10.7314/APJCP.2012.13.9.4757
  2. Roles of Fibroblast Growth Factor-inducible 14 in Hepatocellular Carcinoma vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3509
  3. Therapeutic value of transcatheter arterial chemoembolization combined with portal vein embolization for primary hepatocellular carcinoma with portal vein tumor thrombus: A pilot study vol.11, pp.3, 2015, https://doi.org/10.1111/ajco.12272
  4. Hepatitis B Virus DNA Negativity Acts as a Favorable Prognostic Factor in Hepatocellular Carcinoma Patients vol.15, pp.22, 2014, https://doi.org/10.7314/APJCP.2014.15.22.9635
  5. Drainage Alone or Combined with Anti-tumor Therapy for Treatment of Obstructive Jaundice Caused by Recurrence and Metastasis after Primary Tumor Resection vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2681
  6. Schedule-Dependent Effects of Kappa-Selenocarrageenan in Combination with Epirubicin on Hepatocellular Carcinoma vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3651
  7. Transcatheter Arterial Chemoembolization Combined with Interferon-α is Safe and Effective for Patients with Hepatocellular Carcinoma after Curative Resection vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.245
  8. Transarterial chemoembolization aggravated peritumoral fibrosis via hypoxia-inducible factor-1α dependent pathway in hepatocellular carcinoma vol.30, pp.5, 2015, https://doi.org/10.1111/jgh.12873
  9. Radiofrequency ablation combined with transcatheter therapy in rabbit VX2 liver tumors: effects and histopathological characteristics vol.56, pp.1, 2015, https://doi.org/10.1177/0284185113520266